ERBB3 and cancer: The CDC25C, ErbB3 and FN1 are previously associated with bladder cancer: The activity of CDC25C promotes proliferation and is a target for developing cancer therapies, including bladder cancer [25]; Decreased ErbB3 expression in bladder cancer is associated with poor prognosis [26]; and FN1 is a potential urine biomarker for bladder cancer [27].